glp 1 iih NeuroOp Guru: Stopping GLP-1 therapy may trigger recurrent papilledema in cases | Eye Care Network Infographic: Landmark trials in Neuro-Ophthalmology—results

Hanefeld M, Arteaga JM, Leiter LA, et al

You may have witnessed the excitement surrounding the new classes of medications being used for weight loss: GLP-1 receptor agonists, like Wegovy and Ozempic, and the newer, dual action (GLP1/GIP) medications like Mounjaro and Zepbound

~14-15% on single-receptor GLP-1R agonism a gap that represents the measurable GIP receptor contribution

A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks

A standard Wegovy taper takes 812 weeks, with dose reductions every 23 weeks

Instead, Lemme GLP-1 Daily takes a different approach, using three clinically-studied ingredients that may help support the body's natural hormone production and appetite signaling pathways